Year: 2008
Type: article
Abstract: by CANHUI GUO In the tumors that maintain the wild type p53 tumor suppressor gene, p53 activity is frequently inactivated by a variety of mechanisms, such as, overexpression of Mdm2 or MdmX, loss of Arf, or expression of human papilloma virus protein E6. None of these mechanisms, however, explains the suppressed p53 function in the majority of renal cell carcinomas (RCC), tumors that largely have wild type p53. In our previous study, we found that a small molecule, 9-aminoacrindine (9AA) can restore p53 function in RCC and strongly stimulate activity of wild type p53 in other types of cancer cells. In addition, this compound was found capable of inhibiting NF-kB signaling, the pathway that is constitutively active in RCC as well as in the majority of other tumor types. To determine the mechanism of simultaneous modulation of p53 and NF-kB by 9AA we compared global gene and protein expression profiles of two 9AA-treated and untreated RCC cell lines. The set of genes that changed their expression in response to 9AA treatment contained many known p53and NF-kB targets and therefore was consistent with p53 activation and NF-kB suppression by this compound. Proteomics analysis revealed P110gamma, one of the catalytic subunits of PI3K, to be one of
Author: Canhui Guo
Institution: Case Western Reserve University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2338650512
